6
Participants
Start Date
June 25, 2018
Primary Completion Date
May 18, 2020
Study Completion Date
May 18, 2020
PRO 140
2 injections of PRO 140 (2 X 2 mL/inj.) Subjects who were previously enrolled and receiving 350 mg dose had the option to move to the 700mg dose for the remainder of the trial.
CD02_OpenLabel Investigational Site, Syracuse
CD02_OpenLabel Investigational Site, Decatur
CD02_OpenLabel Investigational Site, Orlando
CD02_OpenLabel Investigational Site, Miami
CD02_OpenLabel Investigational Site, Miami
CD02_OpenLabel Investigational Site, Miami
CD02_OpenLabel Investigational Site, West Palm Beach
CD02_OpenLabel Investigational Site, Ft. Pierce
CD02_OpenLabel Investigational Site, Chicago
CD02_OpenLabel Investigational Site, Wichita
CD02_OpenLabel Investigational Site, Houston
CD02_OpenLabel Investigational Site, Houston
CD02_OpenLabel Investigational Site, Bellaire
CD02_OpenLabel Investigational Site, Palm Springs
CD02_OpenLabel Investigational Site, San Francisco
CD02_OpenLabel Investigational Site, Spokane
CD02_OpenLabel Investigational Site, New Haven
Lead Sponsor
Collaborators (1)
Amarex Clinical Research
OTHER
CytoDyn, Inc.
INDUSTRY